A clinical-stage biotechnology company focused on developing immunology therapies for severe autoimmune and inflammatory diseases. Its pipeline centers on targeting immune pathways such as CD6 to treat conditions including graft-versus-host disease and other immune-mediated disorders. With no approv...
No congressional trades have been disclosed for Equillium, Inc. (EQ) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.